Files
Download Full Text (745 KB)
Publication Date
4-29-2020
Disciplines
Pharmacy and Pharmaceutical Sciences
Abstract
Kasey Rubin PharmD.
Samuel Jacobson PharmD. BCOP, Shannon Buxell PharmD.
Providence Health & Services, Portland Oregon
Pharmacoeconomic impact of patient-centric oncology service model
Providence Health & Services recently embedded ambulatory oncology pharmacists into the ambulatory oncology clinic setting. The overall purpose of this retrospective study is to quantify the financial benefits of ambulatory oncology pharmacists as well as quantify patient-centric factors through utilization of an onsite specialty pharmacy. This study was submitted and approved by Institutional Review Board. Electronic health records of patients who visited the ambulatory oncology clinic will be retrospectively reviewed over two time periods: 12 months preceding integration of a pharmacist and 12 months post integration of a pharmacist on the ambulatory oncology team at Providence Portland Medical Center (PPMC). Each group will consist of 250 patients. The following patient data will be collected: Patient MRN, Patient visit encounter (if multiple visits), sex, ICD10 code for diagnosis, number of prescriptions/dispense report, cost of medication, financial revenue, nausea scores, pain scores, and number of Interventions completed by pharmacists. These endpoints will be assessed and an estimated dollar amount will be attached to each non-monetary service provided by pharmacists. Epic projects an equivalent dollar amount per each intervention completed by a pharmacists. This projected dollar amount will be utilized to quantify the benefits of a pharmacist and will be considered as cost-savings. Number of prescriptions/dispense report and cost data will be provided by Providence specialty pharmacy, Credena. Credena utilizes Epic and CPR+. The primary investigator will not access to CPR+ and will defer to secondary investigators to collect prescription data.
Preliminary pharmacoeconomic data will be presented. Clinical results from the addition of the pharmacists show an initial review of the oral antineoplastic in 70% and 86% of patients in sites #1 and #2, respectively. Follow-up calls were made to 55% and 85% of patients in sites #1 and #2, respectively. Patients getting their prescriptions through Credena are continually counseled by Credena specialty pharmacists. Pharmacists reviewing medications reviewed drug-drug interactions, with the true number of interventions not able to be calculated. In conclusion, pharmacists have added both financial and patient centered benefits after integration with the care team.
Specialty/Research Institute
Pharmacy
Specialty/Research Institute
Graduate Medical Education
Conference / Event Name
Academic Achievement Day, 2020
Location
Providence Portland Medical Center, PGY-1 Pharmacy Residency Program
